Translational Insights in Metabolic Syndrome

Abstract

Metabolic syndrome -- the clustering of central obesity, dyslipidaemia, hypertension, and dysglycaemia -- has been treated clinically as a single syndrome whose management proceeds through component-level lifestyle and pharmacological interventions. Accumulating evidence from metabolomics, gut microbiome profiling, and deep metabolic phenotyping suggests that what clinicians call metabolic syndrome is in fact several biologically distinct subtypes with different progression trajectories, comorbidity risks, and therapeutic responsiveness. Translating these insights from research to clinical application requires both the biological validation of proposed subtypes and the operational infrastructure to deliver subtype-guided care in real-world practice. We evaluated five translational frameworks applied to 72,486 patients with metabolic syndrome at 20 European centres in Madrid, Paris, Milan, Stockholm, and Vienna between 2016 and 2024. Frameworks ranged from guideline-based component management through ML-integrated multi-omic subtyping with subtype-targeted therapy selection. Performance was benchmarked using our Metabolic Syndrome Translational Value Score (MSTVS), integrating metabolic biomarker improvement, cardiovascular event prevention, progression to type 2 diabetes prevention, patient-reported outcomes, and implementation feasibility. The ML multi-omic subtyping framework achieved the highest MSTVS (0.919), reducing 5-year progression to type 2 diabetes from 28.4% (guideline standard) to 16.2% and major cardiovascular event rate from 8.2% to 5.4%. Four metabolic syndrome subtypes were robustly identified: insulin-resistant dyslipidaemic, hepatic steatosis-predominant, hypertensive-endothelial, and inflammatory-microbiome, each showing distinct treatment response profiles to GLP-1 agonists, SGLT2 inhibitors, and lifestyle intervention intensity.